Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Gains from Investment Securities (2019 - 2025)

Nurix Therapeutics (NRIX) has disclosed Gains from Investment Securities for 7 consecutive years, with -$32.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Gains from Investment Securities fell 1256.37% to -$32.5 million in Q4 2025 year-over-year; TTM through Nov 2025 was -$23.9 million, a 681.88% decrease, with the full-year FY2024 number at $4.1 million, down 82.88% from a year prior.
  • Gains from Investment Securities was -$32.5 million for Q4 2025 at Nurix Therapeutics, down from $5.8 million in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $24.0 million in Q4 2023 to a low of -$32.5 million in Q4 2025.
  • A 5-year average of -$14101.8 and a median of $126386.5 in 2021 define the central range for Gains from Investment Securities.
  • Peak YoY movement for Gains from Investment Securities: surged 5534.78% in 2024, then plummeted 1256.37% in 2025.
  • Nurix Therapeutics' Gains from Investment Securities stood at -$12.8 million in 2021, then skyrocketed by 139.59% to $5.1 million in 2022, then soared by 373.46% to $24.0 million in 2023, then crashed by 88.29% to $2.8 million in 2024, then tumbled by 1256.37% to -$32.5 million in 2025.
  • Per Business Quant, the three most recent readings for NRIX's Gains from Investment Securities are -$32.5 million (Q4 2025), $5.8 million (Q3 2025), and $2.8 million (Q4 2024).